Sun Pharma Acquires Checkpoint Therapeutics
May 30, 2025
Sun Pharmaceutical Industries Limited has completed the acquisition of Checkpoint Therapeutics, Inc., acquiring all outstanding shares for $4.10 per share in cash plus a contingent value right. The deal gives Sun Pharma ownership of UNLOXCYT (cosibelimab-ipdl), the FDA-approved anti-PD-L1 therapy for advanced cutaneous squamous cell carcinoma, and expands its oncology/onco-derm product portfolio.
- Buyers
- Sun Pharmaceutical Industries Limited
- Targets
- Checkpoint Therapeutics, Inc.
- Sellers
- Fortress Biotech, Inc., Armistice Capital Master Fund Ltd. (managed by Armistice Capital LLC)
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.